

Special Issue

Clinical and Immunological Therapy for Solid Tumors

Message from the Guest Editor

In recent years, immunotherapies for solid tumors have generated spectacular outcomes for cancer patients in clinics. Adoptive cell therapies (ACT), including using autologous tumor-infiltrating lymphocyte (TILs), TCR T-cells (TCR-engineered T cell), chimeric antigen receptor (CAR) T cells, tumor vaccines and checkpoint blockade, have emerged as the most effective treatments for solid tumors. The current challenge for solid cancer immunotherapies is that although some patients have benefited from these treatments, many cancers will still have variable responses. The purpose of this Special Issue is to understand the treatment advantages and disadvantages in order to provide exciting opportunities for effective anticancer immunotherapies for solid tumors. This Special Issue welcomes reviews, as well as original research articles, which should be submitted by 30 June 2024.

Guest Editor

Dr. Biaoru Li

Department of Pediatrics Hematology/Oncology, Medical College of Georgia, Augusta, GA, USA

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/182083

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)